92 results about "FOOD EFFECT" patented technology

Pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC_0-24 value (AUC_{fibric acid}/AUC_atorvastatin) of between about 250 and about 10,000. The solid compositions are manufactured without any need of addition of water or aqueous medium. Atorvastatin is optionally provided as a controlled release or a delayed release formulation resulting in a maintained LDL-lowering effect at a reduced dosage, and fenofibrate is provided in a formulation having increasing bioavailability and reduced food effect.

The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising sirolimus (rapamycin) and/or derivatives and/or analogues thereof. Compositions of the invention exhibit an acceptable bioavailability of sirolimus and/or a derivative and/or an analogue thereof. The pharmaceutical compositions of the invention are designed to release sirolimus in a controlled manner so that the plasma levels stays within the narrow therapeutic window that exist for this class of substances. An extended release profile, where the peak concentration has been reduced without loosing significant bioavailability, together with less variable absorption, is expected to improve the safety/efficacy ratio of the drug. Furthermore, compositions according to the invention provide for a significant reduced food effect and a delayed release of sirolimus is expected to reduce the number of gastro-intestinal related side effects.

The invention belongs to the technical field of medicines and relates to a puerarin nanocrystalline medical composition and a preparation method and application thereof. Specifically, the puerarin composition is a puerarin nanocrystalline composition. The puerarin composition provided by the invention remarkably improves the solubility and bioavailabilityof puerarin and reduces or eliminates the food effect of the medicine, and is good in stability and can be prepared into various common preparation forms easily, the stability and effect of the medicine are improved, so that the composition has good prospect.

A method of treatment to avoid bioavailability food effects and improve bioavailability variability, by administering a pharmaceutical dosage form containing a pharmaceutical active agent and a disintegrant in a core, a swellable coating surrounding the core, and an optional enteric coating surrounding the swellable coating.

A fibrate self-emulsifying oral formulation with improved bioavailability when compared to commercially available formulations containing a therapeutically effective dose of fenofibrate, derivative of fenofibrate or mixtures thereof dissolved in a fibrate solubilizer selected from N-alkyl derivative of 2-pyrrolidone, mono- or di- or polyethylene glycol monoethers, C_8-12 fatty acid mono- or di-esters of propylene glycol, or combinations thereof, one or more surfactants and optionally one or more stabilizers useful in the treatment of hypercholesterolaemia or hypertriglyceridaemia in mammals in the fed or fasted state.

The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect.

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., C_max, AUC_0-t and/or AUC_0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

The invention relates to a purple corn paste and a production method thereof. The method comprises the following steps: mixing and crushing purple corn grains and frumentum accessories; spraying water and humidifying the crushed raw materials; then, carrying out puffing processing and cutting the major ingredient into short strips; crushing the puffed short strips into major ingredient powder; stir-frying flavor and nutrition accessories to ripeness and crushing the ripe accessories; evenly mixing the flavor and nutrition accessories and the major ingredient powder; carrying out drying and sterilization on the mixture; finally, adding seasoning and evenly mixing the mixture. The invention has the advantages that the purple corn paste is purely natural anthocyanin food, anthocyanin in the purple corn is the best variety in terms of effect among all plant anthocyanins and is superior to other anthocyanin food in terms of food effect; the purple corn paste contains a large amount of purple corn anthocyanin, thus being nutritious and safe to eat; the paste enjoys typical corn food flavor and achieves a good combination of color, aroma and taste; the paste is in line with the traditional dietary habit and meets the demand of mass consumption; the purple corn features high yield of raw material per unit area, low plantation cost and simple cultivation technique, and can be planted widely, thus enjoying abundant sources of the raw material and product processing features simple technology, easy operation, low cost and high economic benefit.

The present invention provides a tamsulosin hydrochloride sustained-release capsule. The tamsulosin hydrochloride sustained-release capsule of the present invention can avoid the sudden release of the drug tablets and the performance differences generated from the gastric emptying differences, display minor food effect or do not display food effect, and obtain the stable curve of the plasma drug concentration and longer action time simultaneously, so as to reduce the occurrence of cardiovascular side effects, greatly improve the safety, effectiveness and compliance of the medication for the patients. The tamsulosin hydrochloride sustained-release capsule of the present invention can ensure the sustained and regular release of the main ingredient tamsulosin hydrochloride after the oral administration, and the present invention is characterized by convenient administration, durable function, stable efficacy, fewer side effects and so on.

The present disclosure relates to pharmaceutically acceptable complex formulae comprising complexes of Abiraterone acetate and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present disclosure have improved physicochemical properties which results in reduced food effect which allows significant dose reduction and the abandoning of the requirement of taking the drug on an empty stomach.

A Ramipril formulation rapidly disintegrates after ingestion and exhibits substantially no food effect.

The invention relates to an oral pharmaceutical composition of isotretinoin at least two excipients, one of the excipients being a hydrophilic excipient having an HLB value greater than or equal to 10 and the other excipient being an oily vehicle. The oral pharmaceutical composition is substantially devoid of food effect as characterized by a dissolution profile wherein at least 70% of the oral pharmaceutical composition is dissolved after about four hours in a USP2 dissolution apparatus at a paddle speed of 100 rpm, and a dissolution media composed of 900 mL of pH 7.5 buffer containing 0.11% pancreatin, 4.7% cholic acid, 0.14% sodium dihydroxide phosphate and 0.5% sodium hydroxide at 37° C.

The invention relates to the technical field of fermented food processing, and in particular relates to a plant enzymatic cooking wine and a preparation method of the plant enzymatic cooking wine. The cooking wine is obtained by fermenting plant stems, medicinal herbs and edible flavoring plants. The plant enzymatic cooking wine and the preparation method of the plant enzymatic cooking wine are scientific in formula, simple in technology and low in production cost; all the plants are combined and fermented, the plant enzymatic cooking wine does not contain additive and contains medicinal components, and the vitamins, mineral substances, amino acids and various enzymes beneficial to the human body in the plant raw materials are protected to the utmost extent, so that the food effects and the use safety are greatly improved; the plant enzymatic cooking wine has the functions of balancing the nutrition and the five internal organs, is used for seasoning the dishes which are eaten in the daily life, and has the effects of adjusting the acid-base balance of the human body, eliminating fatigue, reducing cholesterol and improving the immunity of the human body.

It relates to a lurasidone solid dispersion and a preparation method, wherein the method comprises melting treatment of a mixture containing lurasidone, a medicinal hot melt carrier, optionally an acidic regulator and plasticizer in order to obtain the solid dispersion described herein, and wherein the lurasidone is provided in a form of free base. The lurasidone solid dispersion obtained by the preparation method according to the example of the invention has the characteristics of high dissolution rate (dissolution rate can reach 30%-70%) in a partial neutral medium (e.g. pH 6.0). The bioavailability of lurasidone solid dispersion increased significantly and the food effect of lurasidone solid dispersion prepared from the example decreased remarkably. It overcomes the limitation of too many medication in the prior art and avoids the reduction of curative effect of the improper medication for the patient or even invalid, ensures the normal efficacy, thereby increases the patient's medication flexibility and compliance.

The invention provides a Chinese yam and buckwheat biscuit having the healthcare effect on the diabetes. According to the biscuit, after Chinese yam powder and buckwheat powder are mixed according to the weight ratio of 1:1-4, baking is performed according to a conventional biscuit making method, and then the biscuit can be made and packaged. According to the biscuit, the Chinese yam and the buckwheat which have both the medicine effect and the food effect are adopted as components and mixed reasonably, the obtained Chinese yam and buckwheat biscuit having the healthcare effect on the diabetes is formed by ingeniously combining pure medicine and food, the biscuit has great advantages for reconstructing a glucostasis system of a human body, the appetite of a diabetes patient can be increased through biological and chemical reaction in the human body, meanwhile the glucose index can also be reduced, the biscuit can be taken for a long time, no toxic and side effect exists, the effect of integrating food, healthcare products and medicine is achieved, the medicine making method of traditional Chinese medicine is carried forward continuously, the making method is simple, raw materials are easy to obtain, cost is low, and the curative effect is good.

The invention discloses substitutional tea with the effects of loosening the bowel to relieve constipation, melting turbidity and reducing lipid. The substitutional tea is characterized in that the tea is prepared from bunge cherry seeds, semen cassia, almonds, peach seeds, lotus leaves and parched hawthorn fruit, raw materials are cleaned and processed into a powder extract, and the powder extract is matched with black sesame honey powder, and the substitutional tea is prepared through the steps of mixing, pelletizing and packing. According to the substitutional tea with the effects of loosening the bowel to relieve constipation, a Chinese medical theory is exerted, food materials with the homology of medicine and food are chosen for scientific matching, in the formula, the bunge cherry seeds can loosen the bowel to relieve constipation, descend qi and disinhibit water, semen cassia can remove liver-fire for improving eyesight, and loosen the bowel to relieve constipation, the two components have the effects of inhibiting depletion of fluid causing intestinal dryness, food accumulation and qi depression and abdominal distension and constipation, almonds, peach seeds, black sesame and honey can moisten the intestines and relax the bowels, lotus leaves and parched hawthorn fruit have the effects of reducing lipid, the medical and food effects of all the matched components have complementary advantages, and jointly have the effects of moistening the intestines and relaxing the bowels, melting turbidity and reducing lipid, and it is proved by senior herbalist doctors and consumer crowds through long-term application that the substitutional tea with the effects of loosening the bowel to relieve constipation, melting turbidity and reducing lipid is not only good in effect, but also low in price, convenient to drink and good in mouthfeel.